Lastly, a phase I trial that is currently recruiting will attempt to evaluate the combination of ZEN003694, a BET inhibitor (BETi), with the HDAC entinostat in patients with hematologic malignancies, as well as those with solid tumors overexpressing BET (NCT05053971). This evidence concerns the gene DNER and hematologic disorder.